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In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DAREPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the out
comes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in
patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among
double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For
double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that
the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.

1. Introduction
Diffuse Large B-cell lymphomas (DLBCLs) are by far the most com
mon non-Hodgkin’s lymphomas (NHLs) [1]. DLBCL is a heterogeneous
[2], highly aggressive [3], clonal neoplasm of large B-lymphoid cells
originating from germinal centers. The disease is characterized by
massive lymphadenopathy and constitutional symptoms [4] and con
stitutes 40% of all NHLs globally, with a higher prevalence in developing
countries [5]. Indeed, a study from Pakistan found 76.4% of all NHLs to
be diagnosed as DLBCLs [6].
In keeping with this, the treatment of DLBCLs is under extensive
research. Half a century ago, the standard of treatment regimen was a
combination of chemotherapy with cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) [7]. This regimen resulted in
response rates of 45–55%, with 30–40% of patients achieving cure [7,
8]. Despite the advent of newer regimens, CHOP remained the mainstay
of therapy for decades because of superior cure rates and lesser toxicity
[8]. Recently, a new regimen, with the addition of rituximab to the
previous combination chemotherapy (R-CHOP) showed promise with

better cure rates (of 50–60%) [4] without increased toxicity [9]. Despite
the success of R-CHOP, there are important shortcomings to this com
bination chemotherapy. Liu et al. reported that, of the 40% of patients
who have refractory disease or those who relapse, most patients will not
respond to this chemotherapy [4]. Considering this, newer regimens are
being investigated to improve survival. One such combination is
dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophos
phamide, and doxorubicin (DA-REPOCH) [7]. However, studies
comparing the effectiveness of R-CHOP with that of DA-REPOCH have
been inconclusive. Bartlett et al. found no difference between the two
treatments [10]. Yet, Knouse et al. reported that while there was no
improvement in survival between the two treatments, fewer patients in
the DA-REPOCH arm relapsed or progressed after treatment [7], sug
gesting that the benefits of this new treatment must be re-evaluated.
With results of prior studies inconclusive, it is necessary to assess the
effectiveness of R-DA-EPOCH combination therapy to assess any ad
vantages of this treatment. Thus, this study aims to compare the survival
rates of the DA-REPOCH regimen with the R-CHOP chemotherapy
regimen.

; COO, Cell of Origin; DLBCL, Diffuse large B-cell Lymphoma; OS, Overall Survival; PFS, Progression Free Survival; R-CHOP, rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone; R-DA-EPOCH, rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; WHO,
World Health Organization.
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2. Methods

Table 1
Baseline clinical characteristics of patients with diffuse large B-cell lymphoma.

A retrospective study design was used to investigate the treatment
outcomes of patients previously diagnosed with the either DE or TE
subtype of DLBCL compared with non-expressor DLBCL. A sample of 113
patients who presented to the tertiary care hospital at Karachi, Pakistan
was selected. All consenting patients aged 18 and above, with a diag
nosis of DE or TE subtype of DLBCL as per World Health Organization
(WHO) classification, who were treated between January 1, 2019, to
December 31, 2020, with either DA-REPOCH or R-CHOP, were included
in the study. Patients with a history of prior treatment for aggressive or
indolent lymphoma were not included. All toxicities that were reported
were graded using the common terminology criteria for adverse events,
version 5.0 [11]. Participants’ demographic characteristics, such as age,
sex, and co-morbidities; disease characteristics, such as disease stage,
cell of origin, expressors, and International Prognostic Index (IPI) scores;
and treatment variables, such as the type of treatment given, and the
number of chemotherapy cycles were recorded in the study. The data
were analyzed using STATA version 16.0. All independent and outcome
variables were analyzed descriptively. Normally distributed continuous
variables were represented as means and standard deviations while
categorical variables were presented as frequency counts and percent
ages. Progression-free survival (PFS) and overall survival (OS) were
calculated in months using the Kaplan-Meier survival function. In
addition, the log-rank test was conducted to compare survival distri
butions. Cox proportional hazard regression model was used to analyze
the results [12]. Univariate analysis was conducted to assess the sig
nificance of variables. Then the inter-variable multicollinearity was also
assessed. All variables with a significance of ≤0.25 were admissible in
the multivariable model and significant variables without multi
collinearity were analyzed at p-value ≤0.05 on multivariable analysis.

Variables

Expressors n = 113 (n%)
Non-Expressor
Double/Triple expressor (n = 69)
(n = 44)
R-CHOP
R-DAR-CHOP
Others
EPOCH

Age (Mean ±SD)

52.5 (±15.5)

50
(±14.7)

56.6
(±11.1)

63.8
(±9.0)

30 (68.2)
14 (31.8)

9 (13.0)
9 (13.0)

22 (31.9)
16 (23.2)

9 (13.0)
4 (5.8)

16 (36.4)
28 (63.6)

8 (11.6)
10 (14.5)

19 (27.5)
19 (27.5)

6 (8.7)
7 (10.2)

1 (2.3)
6 (13.6)
6 (13.6)
31 (70.5)

0 (0.0)
0 (0.0)
2 (2.9)
16 (23.2)

0 (0.0)
3 (4.3)
8 (11.6)
27 (39.1)

0 (0.0)
0 (0.0)
1 (1.4)
12
(17.4)

34 (77.3)
3 (6.8)
4 (9.1)
3 (6.8)
1
3
3

5 (7.2)
3 (4.3)
3 (4.3)
7 (10.1)
1
5
4

15 (21.7)
9 (13.0)
10 (14.5)
4 (5.8)
1
6
4

5 (7.2)
4 (5.8)
1 (1.4)
3 (4.3)
1
6
4

17 (38.6)
27 (61.4)

3 (4.3)
15 (21.7)

4 (5.8)
34 (49.3)

1 (1.4)
12
(17.4)

21 (47.7)
23 (52.3)

5 (7.2)
13 (18.8)

13 (18.8)
25 (36.2)

3 (4.3)
10
(14.5)

Sex
Male
Female
COO subtype
Non-GCB
GCB
Disease Stage
1
2
3
4
Co-morbidities
No-any
Hypertension
Diabetes Mellitus
Others
ECOG (median)
IPI Score (median)
CNS IPI Score
(median)
IT Chemotherapy
No
Yes
No. of Chemotherapy
Cycles
≤5
6

3. Results

Abbreviations: COO subtype, cell of origin subtype; ECOG PS, eastern coop
erative oncology group performance status; GCB, germinal center; IPI, interna
tional prognostic index; LDH, lactate dehydrogenase; R-CHOP, rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DA-EPOCH,
rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide,
and doxorubicin.

A total of 113 patients were treated for DLBCL from January 1, 2019,
to December 31, 2020. The total follow-up was of two years duration (24
months). Out of the 113 patients, 44 (39%) were non-expressors and 69
(61%) had double/triple expressor lymphomas. R-CHOP was given as
standard therapy to 44 (39%) of the DLBCL patients. Of the 69 (61%)
patients with double/triple expressor lymphoma, R-DA-EPOCH was
administered to 18 (26.1%), R-CHOP was administered to 38 (55.1%),
and 13 (18.8%) received other treatment regimens i.e., R-Benda and RCVP.

staging system, with 31 (70.5%) patients from the non-expressor DLBCL
group and 55 (79.7%) patients from the double/triple expressor lym
phoma group. The two main comorbidities were hypertension and dia
betes mellitus, found in 15.9% of NE DLBCL patients and 63.8% of
double/triple expressor lymphoma patients. The median Eastern Coop
erative Oncology Group (ECOG) score in patients with both NE DLBCL
and double/tripe expressor lymphoma was [1]. The median IPI score for
patients with NE DLBCL was 3, while the group with double/triple
expressor lymphoma receiving DA-EPOCH had a score of 5, and the
group with double/triple expressor lymphoma receiving R-CHOP and
other treatment regimens had a score of 6. The median central nervous
system IPI (CNS IPI) score was 3 for patients with NE DLBCL and 4 for
patients with double/triple expressor lymphoma receiving any treat
ment. Among NE DLBCL patients, 23 (52.3%) received 6 cycles of
R-CHOP, while out of the 69 patients with double/triple expressor
lymphoma, 13 (18.8) received 6 cycles of R-DA-EPOCH, 25 (36.2)
received 6 cycles of R-CHOP, and 10 (14.5%) received 6 cycles of other
treatment regimens.
The survival rate in NE DLBCL patients receiving R-CHOP as the
standard treatment was 81.8%, while the survival rate was 82.8%
among double/triple expressor lymphoma patients receiving R-DAEPOCH, and 83.3% among double/triple expressor lymphoma patients
receiving R-CHOP. For those who received treatment other than these
two treatment regimens, i.e., R-Benda and R-CVP, the survival rate was
62.5% (Table 2).

4. Baseline demographic and clinical characteristics of
participants
The baseline characteristics of the patients with non-expressor (NE)
and double/triple expressor lymphoma diagnosed basis of IHC receiving
different treatment regimens (R-DA-EPOCH, R-CHOP, and Others) are
displayed in Table 1. The mean (±SD) age of non-expressor DLBCL pa
tients was 52.5 (±15.5) years, while the mean age of participants with
double/triple expressor lymphoma receiving R-DA-EPOCH was 50
(±14.7) years, R-CHOP was 56.6 (±11.1) years, and those receiving
other treatments was 63.8 (±9.0) years. Out of the 44 non-expressor
DLBCL patients, 30 (68.2%) were male and 14 (31.8%) were female.
Among the 69 patients with double/triple expressor lymphoma, there
were 9 (13%) males and 9 (13%) females in the R-DA-EPOCH arm, and
22 (31.9%) males and 16 (23.3%) females in the R-CHOP arm, and 9
(13%) males and 4 (5.8%) females in the other treatment arm. DLBCL
subtypes were described based on the cell of origin. Among the 44 nonexpressor DLBCL cases, 28 (63.6%) cases had the germinal center B-cell
(GCB) subtype, while among those with double/triple expressor lym
phoma, 36 (52.2%) cases had the subtype with germinal center B-cells
(GCB). They latter received either R-DA-EPOCH, R-CHOP, or other
treatment regimens. Most patients had stage IV disease by Lugano
2
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Table 2
The overall survival rate in patients receiving different chemotherapy regimens
for DLBCL after a two-year follow-up.
Survival rate

Expressors n = 113 (Number of patients%)
Non-Expressor(n = 44)
Double/Triple expressor (n = 69)
R-CHOP
R-DA-EPOCH
R-CHOP
Others

%

81.8

82.8

83.3

62.5

5. Progression-free survival (PFS) and overall survival (OS)
At 2 years, the median PFS for the entire cohort was 19.6 months
(range 2.3- 21.6 months). Median 2-year OS (n = 85) was 16.8 months
(3.3–24 months) while OS till the last follow-up was 22.5 months
(1.5–24 months). Among the NE DLBCL patients, the median
progression-free survival was 10.3 months while the overall survival
was 13.6 months. For double/triple expressor lymphoma patients, in
those receiving R-DA-EPOCH, the PFS was 10.5 months and OS was 13.8
months, in those receiving R-CHOP, the PFS was 10.6 months and OS
was 14.2 months and in those receiving other treatment regimens, the
PFS was 6.6 months and OS 10.6 months (Table 3, Fig. 1, 2& 3).

Fig. 1. Kaplan Meir plot for overall survival (in months) for NE DCBCL and
double/triple expressor lymphoma combined.

6. Description of toxicity by treatment
A description of the toxicity by grade with each treatment regimen is
displayed in Table 4. Adverse events are divided into two broad cate
gories: hematologic and non-hematologic. Most patients had hemato
logic adverse events i.e., neutropenia, pancytopenia, or anemia, and
most had a severity of grade 3 or 4. When excluding hematologic events,
gastrointestinal events were the most common adverse events, with
severity of grade 3 or 4.
7. Univariate and multivariable analysis
The Univariate and Multivariable regression model was applied,
assessing the association between treatment regimen received by the
patient and the outcome, which is given in Table 5. Both univariate and
multivariable analysis showed that the treatment regimen, disease
expressors, and toxicity are significant prognostic factors for overall
survival in DLBCL. The hazard ratio for survival in patients who received
R-CHOP was 1.9 times (95% CI 1.1–6.8) compared to those who
received R-DA-EPOCH or other treatments. The hazard ratio of survival
in patients who received other treatments was 4.3 times (95% CI
1.2–6.5) compared to those who received R-DA-EPOCH or R-CHOP.
Additionally, the hazard ratio of survival in NE DLBCL patients was 2.6
times (95% CI 1.1–6.4) compared to double/triple expressor lymphoma.
Moreover, the hazard ratio of survival in patients who have pancyto
penia was 3.1 times (95% CI 1.6–5.5) compared to neutropenia and
other adverse events, while the hazard ratio of survival in patients who
had other adverse events was 5.6 times (95% CI 1.2–7.7) compared to
neutropenia and pancytopenia.

Fig. 2. Kaplan Meir plot for overall survival (in months) in NE and double/
triple expressor lymphoma.

8. Discussion
The treatment of double/triple expressor DLBCL remains a
Table 3
Progression-free survival and overall survival at 2 years of the follow-up.
Survival rate

Median PFS and OS (in months)
Non-Expressor(n
Double/Triple expressor (n = 69)
= 44)
R-CHOP
R-DARCHOP
Others
EPOCH

Progression Free Survival
(months)
Overall Survival (months)

10.3

10.5

10.6

6.6

13.6

13.8

14.2

10.6

Fig. 3. Kaplan Meir plot for overall survival (in months) in double/triple
expressor lymphoma receiving each of the three treatment regimens.
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Table 4
Description of the toxicity with grade by treatment received (R-DA-EPOCH, RCHOP, and Others).
Adverse Event

Hematologic
Pancytopenia
Neutropenia
Anemia
NonHematologic
Infection
(other)
Gastrointestinal
Electrolyte
Imbalance
Sepsis
Tumor lysis

Grade
1/2, n
(%)
R-DAEPOCH

Grade 3/4, n (%)
RCHOP

Others

R-DAEPOCH

RCHOP

Others

04 (3.5)
02 (1.8)
00 (0.0)
00 (0.0)
01 (0.9)
01 (0.9)
00 (0.0)
00 (0.0)

14
(12.4)
09
(8.0)
01
(0.9)
03
(2.7)
00
(0.0)
02
(1.8)
02
(1.8)
00
(0.0)

02
(1.8)
03
(2.7)
00
(0.0)
01
(0.9)
01
(0.9)
01
(0.9)
01
(0.9)
00
(0.0)

07
(6.2)
01
(0.9)
02
(1.8)
02
(1.8)
02
(1.8)
01
(0.9)
01
(0.9)
01
(0.9)

19
(16.8)
01
(0.9)
05
(4.4)
01
(0.9)
05
(4.4)
03
(2.7)
03
(2.7)
01
(0.9)

01
(0.9)
02
(1.8)
00
(0.0)
01
(0.9)
02
(1.8)
02
(1.8)
01
(0.9)
01
(0.9)

Table 5
Univariate and Multivariable Survival Analysis Reporting Crude and Adjusted
Hazard Ratio with 95% Confidence Interval for overall survival in DLBCL.
Variables
Treatment
REPOCH
RCHOP
Other
Age (years)
Sex
Male
Female
COO subtype
Non-GCB
GCB
Expressors
Double/Triple
Non-expressor
Disease Stage
1–3
4
Co-morbidities
No-any
Hypertension
Diabetes Mellitus
Others
ECOG
IPI Score
CNS IPI Score
IT Chemotherapy
No
Yes
No. of Chemotherapy
Cycles
6
≤5
Toxicity
Neutropenia
Pancytopenia
Others

challenge. Double/triple expressor lymphomas contain both MYC and
BCL-2 and/or BCL-6 expression without translocation. There is a poor
prognosis in patients with expression of both MYC and BCL2 [13].
Hence, studies have shown that double/triple expressor lymphomas
have an invasive, aggressive clinical course and respond poorly to
standard R-CHOP therapy, with an average OS of 5 months to 2 years
[14–16]. In fact, 40% of patients relapse, and mortality rates are high,
even after receiving R-CHOP [8]. Despite this poor course, few treat
ments have proven more effective than R-CHOP at improving survival.
R-DA-EPOCH is a newer regimen that holds promise for the treat
ment of double/triple expressor lymphoma [17]. This study shows that
the survival rate of double/triple expressor lymphoma patients receiving
R-DA-EPOCH is more or less similar to the survival rate of double/triple
expressor lymphoma patients receiving R-CHOP (82.8% vs 83.3%). A
possible reason for this may also be the dominant GCB subtype, with has
present in roughly half of all types, as is also reported in literature [9,
10]. Petrich et al. reported that R-DA-EPOCH showed significant ad
vantages over RCHOP for PFS and OS [17], suggesting that R-DA-E
POCH may demonstrate therapeutic advantages [18]. However, as some
of these studies may be limited by small sample sizes. More recently,
Dodero et al. found similar outcomes for both groups [19]. The authors
also found that treatment in younger patients was more efficacious
because they received a higher dose [19]. Magnusson et al. also reported
no difference between the R-CHOP and R-EPOCH regimens [20]. The
study further looked at the risks of poor outcomes and found LDH to be
associated with poor prognosis. We studied the association of LDH via
the IPI and found no association. While evidence may be varied, it seems
to weight towards no difference between the two regimens.
As the R-DA-EPOCH regimen is administered as a continuous intra
venous infusion, the incidence of adverse reactions is expected to be
high [19]. However, our study also found fewer adverse events in the
R-DA-EPOCH arm compared to the R-CHOP arm (Table 4). Hemato
logical adverse events were the most common, mostly constituting
pancytopenia, followed by neutropenia. Of those receiving R-DA-E
POCH, 9.7% of patients developed pancytopenia, compared to 29.2% of
patients receiving R-CHOP. These adverse events were reversed shortly
after symptomatic treatment. None of the patients developed
chemotherapy-related deaths or secondary malignancy. Ma et al. re
ported no significant difference in adverse effects in patients with
R-DA-EPOCH compared to R-CHOP [18]. However, Knouse et al. has
also reported fewer adverse effects with R-DA-EPOCH [10]. The authors
suggest this may be due to the different age ranges of patients treated

CHR (95%
CI)

p-value

AHR (95%
CI)

p-value

1
1.5 (0.5–5.2)
4.1
(1.1–15.3)
1.01
(1.0–1.4)

0.03

1
1.9 (1.1–6.8)
4.3 (1.2–6.5)

<
0.001

0.22

–

–

1
1.5 (0.7–3.1)

0.32

-

-

1
1.2 (0.6–2.5)

0.67

-

-

1
2.5 (1.1–5.9)

0.08

1
2.6 (1.1–6.4)

<
0.001

1
2.64
(1.5–4.2)

<
0.001

-

-

1
1.4
1.6
1.5
1.3
1.2
1.0

0.74

-

-

0.29
0.13
0.9

–
–
–

–
–
–

1
1.9 (0.6–5.4)

0.21

-

-

1
1.4 (0.7–3.0)

0.35

-

-

1
1.9 (0.4–8.8)
3.6
(0.8–15.8)

0.08

1
3.1 (1.6–5.5)
5.6 (1.2–7.7)

<
0.001

(0.5–3.9)
(0.6–4.4)
(0.5–4.2)
(0.8–2.3)
(0.9–1.6)
(0.7–1.6)

Abbreviations: COO subtype, cell of origin subtype; ECOG PS, eastern coop
erative oncology group performance status; GCB, germinal center; IPI, interna
tional prognostic index; LDH, lactate dehydrogenase; R-CHOP, rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DA-EPOCH,
rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide,
and doxorubicin; CHR: Crude Hazard Ratio; AHR: Adjusted Hazard Ratio.

with either regimen, as more patients in the R-CHOP arm were aged at
least 70 years. However, the difference in age ranges in patients treated
with R-DA-EPOCH and R-CHOP in our study was minimal (56.6 ± 11.1
vs 50 ± 14.7). However, there were some other differences in the
number of patients with a higher stage of disease, comorbidities, and
prognostic scores. Hence, we cannot conclude whether R-DA-EPOCH
has fewer adverse events than R-CHOP. Further studies, with matched
cohorts, may be required to study this.
There are some limitations to our study. It is a single-center study
and has a small sample size of 113 patients due to the rare nature of the
disease. It is also for this reason that we could not balance the baseline
demographic and disease characteristics of patients who received each
treatment. Despite these limitations, this is a prospective study design
that has reported data on the PFS, OS, and adverse effects of treatments
for high-risk DLBCL. It is also the first study of its kind from the local
population.
This study shows similar efficacy of R-DA-EPOCH as compared to RCHOP for the treatment of double/triple expressor lymphoma. We have
also demonstrated fewer adverse effects with R-DA-EPOCH compared
with R-CHOP, suggesting its value as a possible first-line treatment in
4
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high-risk DLBCL. In the future, multicentered studies, with larger sample
sizes, equal distribution of treatments, and matching, are required to
better compare the efficacy and safety of R-DA-EPOCH with that of RCHOP in the treatment of double/triple expressor lymphoma to improve
progression-free survival and overall survival in this aggressive disease.

Aga Khan University Hospital for their logistic support and Department
of Health Management and Information Systems (HIMS), Aga Khan
University Hospital for their support in data processing.
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